Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.
Vernon Jansen Unit, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Am J Physiol Renal Physiol. 2022 Aug 1;323(2):F156-F170. doi: 10.1152/ajprenal.00277.2021. Epub 2022 Jun 13.
The lysosomal storage disease cystinosis is caused by mutations in , encoding the cystine transporter cystinosin, and in its severest form leads to proximal tubule dysfunction followed by kidney failure. Patients receive the drug-based therapy cysteamine from diagnosis. However, despite long-term treatment, cysteamine only slows the progression of end-stage renal disease. Preclinical testing in cystinotic rodents is required to evaluate new therapies; however, the current models are suboptimal. To solve this problem, we generated a new cystinotic rat model using CRISPR/Cas9-mediated gene editing to disrupt exon 3 of and measured various parameters over a 12-mo time course. rats display hallmarks of cystinosis by 3-6 mo of age, as demonstrated by a failure to thrive, excessive thirst and urination, cystine accumulation in tissues, corneal cystine crystals, loss of LDL receptor-related protein 2 in proximal tubules, and immune cell infiltration. High levels of glucose, calcium, albumin, and protein were excreted at 6 mo of age, consistent with the onset of Fanconi syndrome, with a progressive diminution of urine urea and creatinine from 9 mo of age, indicative of chronic kidney disease. Kidney histology and immunohistochemistry showed proximal tubule atrophy and glomerular damage as well as classic "swan neck" lesions. Overall, rats show a disease progression that more faithfully recapitulates nephropathic cystinosis than existing rodent models. The rat provides an excellent new rodent model of nephropathic cystinosis that is ideally suited for conducting preclinical drug testing and is a powerful tool to advance cystinosis research. Animal models of disease are essential to perform preclinical testing of new therapies before they can progress to clinical trials. The cystinosis field has been hampered by a lack of suitable animal models that fully recapitulate the disease. Here, we generated a rat model of cystinosis that closely models the human condition in a timeframe that makes them an excellent model for preclinical drug testing as well as being a powerful tool to advance research.
溶酶体贮积病胱氨酸病是由编码胱氨酸转运蛋白胱氨酸的基因突变引起的,在其最严重的形式中,导致近端肾小管功能障碍,随后发生肾衰竭。患者从诊断开始就接受胱氨酸酶药物治疗。然而,尽管进行了长期治疗,胱氨酸酶只能减缓终末期肾病的进展。需要在胱氨酸病啮齿动物中进行临床前测试来评估新的治疗方法;然而,目前的模型并不理想。为了解决这个问题,我们使用 CRISPR/Cas9 介导的基因编辑生成了一种新的胱氨酸病大鼠模型,以破坏 和外显子 3,并在 12 个月的时间过程中测量各种参数。 在 3-6 个月大时表现出胱氨酸病的特征,表现为生长不良、过度口渴和排尿、组织中胱氨酸积累、角膜胱氨酸晶体、近端肾小管中 LDL 受体相关蛋白 2 丢失以及免疫细胞浸润。6 个月大时,高水平的葡萄糖、钙、白蛋白和蛋白质被排出,与范可尼综合征的发作一致,从 9 个月大时开始,尿液尿素和肌酐逐渐减少,表明慢性肾脏病。肾脏组织学和免疫组织化学显示近端肾小管萎缩和肾小球损伤以及典型的“天鹅颈”病变。总的来说, 大鼠表现出的疾病进展比现有的啮齿动物模型更能真实地再现肾性胱氨酸病。 大鼠为肾性胱氨酸病提供了一种极好的新的啮齿动物模型,非常适合进行临床前药物测试,是推进胱氨酸病研究的有力工具。疾病动物模型对于在进行临床试验之前对新疗法进行临床前测试至关重要。胱氨酸病领域一直受到缺乏完全再现疾病的合适动物模型的阻碍。在这里,我们生成了一种胱氨酸病大鼠模型,该模型在时间范围内非常接近人类疾病,非常适合进行临床前药物测试,并且是推进研究的有力工具。